In addition, five therapeutic targets for NAFLD (CXCL10, ENO3, INHBE, LRRC31, and OPTN) and several potential therapeutics, including digoxin, were identified. This evidence concerns the gene ENO3 and metabolic dysfunction-associated steatotic liver disease.